The Relationship Between the Microbiome and Antimicrobial Resistance.

Autor:	Nhu NTQ; Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA., Young VB; Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.; Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Jazyk:	angličtina
Zdroj:	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2023 Dec 05; Vol. 77 (Suppl 6), pp. S479-S486.
DOI:	10.1093/cid/ciad641
Abstrakt:	Antibiotics have benefitted human health since their introduction nearly a century ago. However, the rise of antibiotic resistance may portend the dawn of the "post-antibiotic age." With the narrow pipeline for novel antimicrobials, we need new approaches to deal with the rise of multidrug resistant organisms. In the last 2 decades, the role of the intestinal microbiota in human health has been acknowledged and studied widely. Of the various activities carried out by the gut microbiota, colonization resistance is a key function that helps maintain homeostasis. Therefore, re-establishing a healthy microbiota is a novel strategy for treating drug resistance organisms. Preliminary studies suggest that this is a viable approach. However, the extent of their success still needs to be examined. Herein, we will review work in this area and suggest where future studies can further investigate this method for dealing with the threat of antibiotic resistance. Competing Interests: Potential conflicts of interest. V. Y. reports grant support from the National Institutes of Health (NIH) and National Institute for Allergy and Infectious Diseases (NIAID); collaboration on phase 1 trial of VE303 in patients with hepatic encephalopathy with Vedanta biosciences; consulting fees from Vedanta Biosciences and Debiopharm; honoraria payments from Oklahoma University Health Sciences Center, Illinois Society for Microbiology, and Michigan State University; support for attending the American Society for Microbiology meeting; participation in the VRBPAC meeting regarding the approval application of RBX2660 by Ferring Pharmaceuticals; holds leadership roles with the American Society for Microbiology and the Peggy Lillis Foundation; and is the journal senior editor of mSphere and chair of the council on microbial sciences with the American Society for Microbiology. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu